Association between a variant in the 11 beta-hydroxysteroid dehydrogenase type 2 gene and primary hypertension. 2000

O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
Department of Endocrinology, Lund University, Malmö, Sweden. Olle.Melander@endo.mas.lu.se

The enzyme 11 beta-hydroxysteroid dehydrogenase type 2 (11BHSD2) converts cortisol to cortisone in the kidney, thereby protecting the mineralocorticoid receptor from the mineralocorticoid actions of cortisol. The syndrome of Apparent Mineralocorticoid Excess (AME), a rare monogenic form of early onset hypertension with autosomal recessive inheritance, is caused by homozygous or compound heterozygous loss of function mutations in the 11BHSD2 gene. Association has been reported between a microsatellite marker flanking the 11BHSD2 gene (D16S496) and primary hypertension. The aim of this study was to identify variants in the 11BHSD2 gene and to test if such variants or the D16S496 are associated with primary hypertension, in Swedes. To address this, the coding sequences of the 11BHSD2 gene was screened for mutations in 20 patients with primary hypertension with single strand conformation polymorphism and direct DNA sequencing techniques. A polymorphism was identified in exon 3; G534A (Glu178Glu). This polymorphism and the D16S496 microsatellite were tested for association with primary hypertension in a population consisting of 292 patients with primary hypertension and 263 normotensive control subjects. The frequency of G534G homozygotes was higher in patients with primary hypertension than in normotensive control subjects (92.8% vs 87.8%; P < 0.05). The allele frequencies of the D16S496 microsatellite did not differ between the two groups (chi(2) = 11.0, df = 10; P = 0.36). In conclusion, over-representation of individuals homozygous for the G534 allele in hypertensive patients compared with control subjects suggests that a mutation in linkage disequilibrium with the G534A polymorphism could increase susceptibility to primary hypertension. Journal of Human Hypertension (2000) 14, 819-823

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011110 Polymorphism, Genetic The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. Gene Polymorphism,Genetic Polymorphism,Polymorphism (Genetics),Genetic Polymorphisms,Gene Polymorphisms,Polymorphism, Gene,Polymorphisms (Genetics),Polymorphisms, Gene,Polymorphisms, Genetic
D005260 Female Females
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D006913 Hydroxysteroid Dehydrogenases Enzymes of the oxidoreductase class that catalyze the dehydrogenation of hydroxysteroids. (From Enzyme Nomenclature, 1992) EC 1.1.-. Hydroxysteroid Dehydrogenase,Dehydrogenase, Hydroxysteroid,Dehydrogenases, Hydroxysteroid
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
November 2002, Revista medica de Chile,
O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
June 2002, European journal of clinical investigation,
O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
September 1996, Hypertension (Dallas, Tex. : 1979),
O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
May 1998, The Journal of clinical endocrinology and metabolism,
O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
August 2003, International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity,
O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
June 1994, The Journal of clinical endocrinology and metabolism,
O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
December 1995, The Journal of steroid biochemistry and molecular biology,
O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
January 2000, Anticancer research,
O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
August 2003, Biochemical and biophysical research communications,
O Melander, and M Orho-Melander, and K Bengtsson, and U Lindblad, and L Råstam, and L Groop, and U L Hulthén
October 2004, The Journal of clinical investigation,
Copied contents to your clipboard!